摘要
目的 评价利妥昔单抗联合化疗治疗B细胞性非霍奇金淋巴瘤的有效性和安全性.方法 将52例入组患者分为两组,联合组使用利妥昔单抗联合化疗,对照组单纯进行化疗.结果 联合组临床有效率为92.3%,化疗组为65.4%,两组相比具有统计学意义（P＜0.05）.不良反应发生率两组相比无统计学差异.结论 利妥昔单抗联合化疗治疗B细胞性非霍奇金淋巴瘤的有效率显著提高,且安全性好.
Objective To evaluate the efficacy and safety of Rituximab combined with chemotherapy in treating B-cell non-Hodgkin lymphoma（NHL）.Metbods 52 diagnosed patients with B-cell NHL were divided into two groups,26 cases were treated with Rituximab combined with chemotherapy, while 26 cases were treated with chemotherapy only.Results The total effective rate in Rituximab combined with chemotherapy group were 92.3%,while the chemotherapy group were only 65.4%.The efficacy differences between the two groups had statistical significance（P 〈 0.05）,while the safety differences between the two groups had no statistical significance（P 〉 0.05）.Conclusion Treating B-cell NHL with Rituximab combined with chemotherapy is more effective,whithout additional side-effects.
出处
《中国血液流变学杂志》
CAS
2012年第1期55-56,93,共3页
Chinese Journal of Hemorheology
